Moderna’s CMV vaccine fails Phase 3 study, company to halt most development

Moderna said its cytomegalovirus vaccine failed a Phase 3 study and it will end further development of the shot for most patients. The company said Wednesday that the efficacy of the vaccine, called mRNA-1647, ranged ...